Allogenic transplantation of unrelated donor haematopoyetic progenitors under nonmyeloablative conditions and inmunosuppression with Rapamicina [Trasplante alogenico de progenitores hematopoyeticos de donante no emparentado tras acondicionamiento no mieloablativo e inmunosupresion postrasplante con Rapamicina Alogenic transplantation of unrelated donor hematopoyetic progenitors under nonmieloablative conditions and inmunosuppression with Rapamicina]

Trial Profile

Allogenic transplantation of unrelated donor haematopoyetic progenitors under nonmyeloablative conditions and inmunosuppression with Rapamicina [Trasplante alogenico de progenitores hematopoyeticos de donante no emparentado tras acondicionamiento no mieloablativo e inmunosupresion postrasplante con Rapamicina Alogenic transplantation of unrelated donor hematopoyetic progenitors under nonmieloablative conditions and inmunosuppression with Rapamicina]

Completed
Phase of Trial: Phase II

Latest Information Update: 14 May 2013

At a glance

  • Drugs Sirolimus (Primary) ; Ciclosporin; Mycophenolate mofetil; Tacrolimus
  • Indications Graft-versus-host disease
  • Focus Therapeutic Use
  • Most Recent Events

    • 28 Apr 2012 Actual end date 11 Jan 2011 added as reported by European Clinical Trials Database.
    • 28 Apr 2012 Status changed from recruiting to completed as reported by European Clinical Trials Database.
    • 01 Sep 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top